Men treated with ADT more likely to experience impaired cognitive performance

the ONA take:

Men treated with androgen deprivation therapy (ADT) for prostate cancer were more likely to demonstrate impaired cognitive performance within 6 months and for up to 12 months after initiation of ADT, a new study published online early in the Journal of Clinical Oncology has shown.

For the study, researchers at Moffitt Cancer Center in Tampa, Florida, sought to determine the effect of ADT on cognitive performance identify predictors of impaired performance. Researchers enrolled 58 patients with prostate cancer whom they assessed before or within 21 days of starting ADT and 6 and 12 months afterwards. 

Participants were compared with matched controls with prostate cancer treated with prostatectomy as well as men with without prostate cancer.

Results showed that participants that received ADT had higher rates of impaired cognitive performance over time compared with all controls.

Researchers found that those who received ADT were more likely to exhibit impaired performance within 6 and 12 months versus the other two groups despite no differences in baseline characteristics.

Exploratory genetic analyses showed that GNB3 single-nucleotide polymorphism rs1047776 was associated with higher rates of impaired cognitive performance over time in patients treated with ADT.

The findings may result in changes to patient education regarding the benefits and risks of ADT.

Men treated with ADT more likely to experience impaired cognitive performance
Men treated with ADT for prostate cancer more likely to demonstrate impaired cognitive performance.
Men receiving androgen-deprivation therapy (ADT) for prostate cancer may be at risk for cognitive impairment; however, evidence is mixed in the existing literature.
READ FULL ARTICLE From Ascopubs
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs